Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Zai Lab Limited - American Depositary Shares (NQ:ZLAB)

24.14 UNCHANGED
Streaming Delayed Price Updated: 4:00 PM EDT, Sep 11, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Press Releases about Zai Lab Limited - American Depositary Shares

< Previous 1 2 3 4 5 6 Next >
News headline image
Zai Lab to Announce Full-Year Financial Results and Corporate Updates on March 1, 2023
Company to Host Conference Call and Webcast on March 2, 2023, at 8:00 a.m. ET 
From Zai Lab Limited
Via GlobeNewswire
News headline image
Zai Lab Announces Participation in February Investor Conferences
From Zai Lab Limited
Via GlobeNewswire
News headline image
Zai Lab Announces NDA for Sulbactam-Durlobactam (SUL-DUR) Granted Priority Review by China’s NMPA
From Zai Lab Limited
Via GlobeNewswire
News headline image
Zai Lab Announces Inclusion of QINLOCK® (ripretinib) and NUZYRA® (omadacycline) in China’s National Reimbursement Drug List
From Zai Lab Limited
Via GlobeNewswire
News headline image
Zai Lab Appoints Michel Vounatsos To Its Board of Directors
From Zai Lab Limited
Via GlobeNewswire
News headline image
Zai Lab and Novocure Announce Pivotal LUNAR Study in Non-Small Cell Lung Cancer Met Primary Overall Survival Endpoint
From Zai Lab Limited
Via GlobeNewswire
News headline image
Zai Lab Announces the Appointment of Dr. Rafael G. Amado as President, Head of Global Oncology Research and Development
From Zai Lab Limited
Via GlobeNewswire
News headline image
Zai Lab Announces Participation in January Investor Conferences
From Zai Lab Limited
Via GlobeNewswire
News headline image
Zai Lab Presents Interim Overall Survival Data for ZEJULA® (niraparib) from the NORA Phase 3 Study at the ESMO Virtual Plenary
From Zai Lab Limited
Via GlobeNewswire
News headline image
Zai Lab Partner Mirati Therapeutics Presents Late-Breaking Results Evaluating Concurrent Adagrasib and Pembrolizumab in First-Line Advanced/Metastatic Non-Small Cell Lung Cancer (NSCLC)
From Zai Lab Limited
Via GlobeNewswire
News headline image
Zai Lab Announces Third Quarter 2022 Financial Results and Corporate Updates
From Zai Lab Limited
Via GlobeNewswire
News headline image
Zai Lab to Present New Oncology Research at 2022 Society for Immunotherapy of Cancer Annual Meeting
Poster presentations will highlight Zai’s key internal pipeline programs, ZL-1211 (anti-CLDN18.2 antibody) for gastric cancer and ZL-1218 (anti-CCR8 antibody) for solid tumors 
From Zai Lab Limited
Via GlobeNewswire
News headline image
Zai Lab Announces the Appointment of Dr. Peter Huang as Chief Scientific Officer
From Zai Lab Limited
Via GlobeNewswire
News headline image
Zai Lab Announces Participation in November Investor Conferences
From Zai Lab Limited
Via GlobeNewswire
News headline image
Zai Lab to Announce Third Quarter 2022 Financial Results on November 9, 2022
-- Company to Host Conference Call and Webcast on November 10, 2022, at 8:00 a.m. ET 
From Zai Lab Limited
Via GlobeNewswire
News headline image
Zai Lab Launches its first Trust Report
Outlines Company’s ESG Strategy through its Trust for Life Commitments 
From Zai Lab Limited
Via GlobeNewswire
Global Cervical Cancer Treatment Market Size Expected to Reach $11 Billion By 2027
Palm Beach, FL – October 6, 2022 – FinancialNewsMedia.com News Commentary – The global Cervical Cancer Treatment market has been expanding for several years and is projected to continue at a growing... 
Via FinancialNewsMedia
News headline image
Seagen and Zai Lab Announce Regional Strategic Collaboration and License Agreement for TIVDAK® (tisotumab vedotin-tftv)
From Seagen Inc.
Via Business Wire
News headline image
Novocure and Zai Lab Announce EF-31 Phase 2 Pilot Study Evaluating Tumor Treating Fields Together with Standard-of-Care Chemotherapy Meets Primary Endpoint for First-Line Treatment of Gastric Cancer
From Novocure
Via Business Wire
News headline image
Zai Lab Limited (NASDAQ: ZLAB) Investor Alert: Investigation over Possible Violations of Securities Laws ↗
San Diego, CA -- (SBWIRE) -- 04/25/2022 -- Zai Lab Limited is under investigation over potential securities laws violations by Zai Lab Limited in connection with certain financial statements. 
Via SBWire
News headline image
INVESTIGATION REMINDER: The Schall Law Firm Encourages Investors in Zai Lab Limited with Losses of $100,000 to Contact the Firm
From The Schall Law Firm
Via Business Wire
News headline image
INVESTIGATION ALERT: The Schall Law Firm Encourages Investors in Zai Lab Limited with Losses of $100,000 to Contact the Firm
From The Schall Law Firm
Via Business Wire
News headline image
EQUITY ALERT: Rosen Law Firm Encourages Zai Lab Limited Investors with Losses in Excess of $100K to Inquire About Securities Class Action Investigation – ZLAB
From The Rosen Law Firm, P.A.
Via Business Wire
Promising Developments in Breast Cancer Treatments Ahead in 2022
FN Media Group Presents USA News Group News Commentary Vancouver, BC – January 12, 2022 – USA News Group – So far in 2022, there have already been some impressive developments in the battle against... 
Via FinancialNewsMedia
News headline image
PureTech Founded Entity Karuna Therapeutics and Zai Lab Announce Strategic Collaboration for Development, Manufacturing, and Commercialization of KarXT in Greater China
From PureTech Health plc
Via Business Wire
News headline image
Crescendo Biologics Announces That Zai Lab Has Achieved Proof-of-Concept for ZL-1102 (Humabody®, CB001) in a Phase 1b Clinical Trial in Psoriasis Patients
From Crescendo Biologics Ltd
Via Business Wire
News headline image
Schrödinger and Zai Lab Announce a Global R&D Collaboration in Oncology
From Zai Lab Limited
Via Business Wire
< Previous 1 2 3 4 5 6 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.